Flerie
48.31
SEK
+0.23 %
FLERIE
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
+0.23%
+1.95%
+2.9%
+7.36%
+7.83%
+102.98%
-70.47%
-81.33%
-81.6%
Flerie is an active long-term life science investor with a focus on biotechnology and pharmaceutical investments globally. The company is based in Stockholm and London and manages a portfolio of investments in Europe, Israel and the USA. The main focus is on providing organizations that primarily operate in drug development with services and resources. Flerie was founded in 2011 and has its headquarters in Stockholm.
Read moreMarket cap
3.77B SEK
Turnover
423.74K SEK
Revenue
100K
EBIT %
-275,000 %
P/E
-
Dividend yield-%
-
Coverage
CEO, Sweden
Financial calendar
16.4
2025
Interim report Q1'25
14.5
2025
General meeting '25
31.7
2025
Interim report Q2'25
ShowingAll content types
Invitation to presentation of Flerie’s Year-end report 2024
Flerie’s portfolio company AnaCardio reports positive results from phase 1b study of AC01 in patients with heart failure and reduced ejection fraction, and announces SEK 205 million financing round
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools